Waters Corporation Appoints Wei Jiang to Board of Directors
Waters Corporation (NYSE: WAT) has appointed Wei Jiang to its Board of Directors, effective July 14, 2021. Wei currently serves as Executive Vice President at Bayer Pharmaceuticals for the China and APAC regions. His expertise in driving results in fast-growing markets, particularly in China, is viewed as a significant asset for Waters. Dr. Udit Batra, CEO, notes that Wei's experience aligns with the company's growth strategy in the pharmaceutical sector. Wei expressed enthusiasm about contributing to Waters' ongoing transformation, highlighting growth potential in China's pharma market.
- Wei Jiang's extensive experience in the pharma sector is expected to enhance Waters' strategic direction.
- His previous success in driving results in key growth markets, like China, could support Waters' expansion initiatives.
- The new appointment aligns with Waters' focus on the fast-growing pharmaceutical market in Greater China.
- None.
Waters Corporation (NYSE: WAT) today announced the appointment of Wei Jiang to its Board of Directors, effective July 14, 2021. Mr. Jiang currently serves as Executive Vice President and President, Bayer Pharmaceuticals Region China & APAC and President, Bayer Group Greater China.
Dr. Flemming Ornskov, Chairman of the Board, said, “We are excited to welcome Wei to the Board and know that we will benefit from his operating experience and transformation expertise. Wei has an outstanding record of driving results in regions that represent key growth opportunities for Waters, including China and other Asia-Pacific markets. We believe he is a valuable addition to the Board at this pivotal time for Waters.”
Dr. Udit Batra, President and Chief Executive Officer of Waters Corporation, commented, “Wei’s results-driven experience will bring perspective to the Board that directly aligns with Waters’ strategy to accelerate growth and innovation. We look forward to his insights as we continue to further strengthen our focus on serving customers in the fast-growing and cutting-edge pharma market in Greater China and beyond.”
Mr. Jiang said, “China’s pharma, biopharma and natural products markets are experiencing a surge in growth and innovation. I can’t think of a company better positioned than Waters to serve these customers with the world-class analytical technologies and services that Waters is so well known for. I am honored to join the Board and contribute to the momentum of the Company’s ongoing transformation.”
Mr. Jiang is Executive Vice President and President, Bayer Pharmaceuticals Region China & APAC and President, Bayer Group Greater China, where he is a Member of Pharmaceuticals Executive Committee and responsible for pharma business in China and APAC. He previously held various senior positions at AstraZeneca, culminating in his role as Senior Vice President, China operations. Prior to that, Mr. Jiang served as Managing Director, China operations at Guidant Corporation and in various roles at Eli Lilly & Company including Marketing Director, China Operations. He currently serves on the boards of China Red Cross and R&D Based Pharmaceuticals association. He received his undergraduate degree in economics and finance at Indiana State University and a B.BA. in business administration and finance from Campbell University in North Carolina.
Additional Resources
- Waters Board of Directors
- Connect with Waters via Twitter, Facebook and LinkedIn
About Waters
Waters Corporation (NYSE:WAT), the world's leading specialty measurement company, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food and environmental sciences for more than 60 years. With more than 7,400 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Cautionary Statement
This release contains “forward-looking” statements regarding future results and events, including statements regarding Mr. Jiang’s appointment. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “will,” “feels”, “believes”, “anticipates”, “plans”, “expects”, “intends”, “suggests”, “appears”, “estimates”, “projects”, and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. Actual future results and events may differ significantly from the results and events discussed in the forward-looking statements within this release for a variety of reasons, including the factors that are discussed in the sections entitled “Forward-Looking Statements” and “Risk Factors” of the Company’s annual report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission (“SEC”), as updated by the Company’s subsequent filings with the SEC. The forward-looking statements included in this release represent the Company’s estimates or views as of the date of this release and should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005162/en/
FAQ
Who is the new board member appointed at Waters Corporation?
When did Wei Jiang join the Board of Waters Corporation?
What is Wei Jiang's current position before joining Waters?
How does Wei Jiang's appointment impact Waters Corporation's strategy?
What markets is Waters Corporation focusing on after Wei Jiang's appointment?
